Telik Will Continue Developing Telcyta Despite Three Phase III Failures
This article was originally published in The Pink Sheet Daily
Firm says an independent review shows its ASSIST-3 trial may have been compromised by inappropriately dropped patients.
You may also be interested in...
Telik plans to submit additional safety and other information to FDA and request a meeting with the agency “as soon as possible.”
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.